Active Filter(s):
Details:
The acquisition marks Hikma’s expansion into Canada and a portfolio of 25 sterile injectable products including the marketed product Atropine-G, three in-licenced ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.
Lead Product(s): Atropine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atropine-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Hikma Pharmaceuticals
Deal Size: $45.8 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 17, 2022